Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.42 |
| ▸ | CDH1 | P12830 | 1/20 | 0.40 |
| ▸ | APC | P25054 | 1/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.40 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 5/20 | 0.38 |
| ▸ | RAB9A | P51151 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.35 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.35 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10584287 | 0.93 | ALDH1A1 (0.46) | ALDH1A1NAPRTCDH1APCCTNNB1 | |
| SCHEMBL1574747 | 0.86 | TDP1 (0.54) | ALDH1A1NAPRTCDH1APCCTNNB1 | |
| SCHEMBL29967657 | 0.86 | TDP1 (0.54) | ALDH1A1NAPRTCDH1APCCTNNB1 | |
| Hydrochloric Acid SCHEMBL11208994 | 0.85 | TDP1 (0.53) | ALDH1A1NAPRTCDH1APCCTNNB1 | |
| SCHEMBL25527753 | 0.85 | ALDH1A1 (0.49) | ALDH1A1NAPRTCDH1APCCTNNB1 | |
| SCHEMBL21818455 | 0.81 | HTT (0.52) | ALDH1A1KMT2AHTTHPGDCSNK2A1 | |
| SCHEMBL15060475 | 0.81 | GSK3B (0.46) | ALDH1A1CDH1APCCTNNB1TCF7L2 | |
| SCHEMBL27982016 | 0.81 | ALDH1A1 (0.47) | ALDH1A1NAPRTCDH1APCCTNNB1 | |
| SCHEMBL31133345 | 0.80 | HTT (0.51) | ALDH1A1HTTHPGDCSNK2A1KDM4E | |
| SCHEMBL11144403 | 0.79 | TDP1 (0.54) | ALDH1A1NAPRTCDH1APCCTNNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115403531-A | Chemical entities, compositions, and methods as kinase inhibitors | 润新生物公司 | 2022-11-29 | — | — | CN | disclosed |
| US-20220251049-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2022-08-11 | — | — | US | disclosed |
| CN-108794411-B | Certain chemical entities, compositions, and methods | 润新生物公司 | 2022-06-07 | — | — | CN | disclosed |
| US-20210040048-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2021-02-11 | — | — | US | disclosed |
| US-20210040048-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2021-02-11 | — | — | US | disclosed |
| US-20200390763-A1 | BENZENESULFONAMIDE DERIVATIVES OF QUINOXALINE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN METHODS FOR TREATING CANCER | NEUPHARMA, INC. | 2020-12-17 | — | — | US | disclosed |
| US-20200390763-A1 | BENZENESULFONAMIDE DERIVATIVES OF QUINOXALINE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN METHODS FOR TREATING CANCER | NEUPHARMA, INC. | 2020-12-17 | — | — | US | disclosed |
| US-10759766-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-10759766-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| EP-3332785-B1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA INC (US) | 2020-05-06 | — | — | EP | disclosed |
| WO-2013032951-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013032951-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| US-20130053384-A1 | Certain Chemical Entities, Compositions, and Methods | NEUPHARMA, INC. (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053384-A1 | Certain Chemical Entities, Compositions, and Methods | NEUPHARMA, INC. (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053384-A1 | Certain Chemical Entities, Compositions, and Methods | NEUPHARMA, INC. (US) | 2013-02-28 | — | — | US | disclosed |
| US-20080207616-A1 | Quinoxalines as B Baf Inhhibitors | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| CN-101080396-A | Quinoxalines as B Raf inhibitors | ASTRAZENECA AB (SE) | 2007-11-28 | — | — | CN | disclosed |
| EP-1828147-A1 | QUINOXALINES AS B-RAF INHIBITORS | AstraZeneca AB (SE) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006040568-A1 | QUINOXALINES AS B RAF INHIBITORS | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
| US-4398913-A | ALKALINE PASTES | CASSELLA AKTIENGESELLSCHAFT (DE) | 1983-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200390763-A1 | BENZENESULFONAMIDE DERIVATIVES OF QUINOXALINE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN METHODS FOR TREATING CANCER | PDXK, BRAF, CHEK1 | ALDH1A1 3012/4885NAPRT 668/4885CDH1 4417/4885 |
| US-20210040048-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, NRAS, KRAS | ALDH1A1 955/4885NAPRT 687/4885CDH1 4693/4885 |
| US-20130053384-A1 | Certain Chemical Entities, Compositions, and Methods | BRAF, PIK3CA, PLK1 | ALDH1A1 2001/4885NAPRT 1535/4885CDH1 3924/4885 |
| US-10759766-B2 | Certain chemical entities, compositions, and methods | BRAF, NRAS, KRAS | ALDH1A1 955/4885NAPRT 687/4885CDH1 4693/4885 |
| US-20220251049-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, NRAS, KRAS | ALDH1A1 955/4885NAPRT 687/4885CDH1 4693/4885 |
| US-20080207616-A1 | Quinoxalines as B Baf Inhhibitors | BRAF, NRAS, ARAF | ALDH1A1 1175/4885NAPRT 1041/4885CDH1 3685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.